PAI Pharma acquires Nivagen to boost US injectable drug production
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
After leading AstraZeneca's Oncology areas nationally and internationally, Laura Colón will assume the presidency of AstraZeneca in one of its priority global markets
The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
The supplements are made using only vegetarian-sourced ingredients
The guidelines also support reusing tenofovir and abacavir in later regimens for improved outcomes, cost savings, and programmatic efficiency
NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
Subscribe To Our Newsletter & Stay Updated